Skip to content

The Impact of Optimized Vonoprazan Administration Time on the Eradication Rate of Helicobacter Pylori in Dual Therapy Containing Vonoprazan: A Prospective, Single-Center, Open-Label Randomized Controlled Trial

The Impact of Optimized Vonoprazan Administration Time on the Eradication Rate of Helicobacter Pylori in Dual Therapy Containing Vonoprazan: A Prospective, Single-Center, Open-Label Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117905
Enrollment
Unknown
Registered
2026-01-29
Start date
2026-01-29
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hylicobacter pylori infection

Interventions

Group A:Vonoprazan 20mg twice a day taken 30 minutes before breakfast and dinner Amoxicillin 1.0g taken three times a day (half an hour after the meal) ,14day
Group B:Vonoprazan 20mg twice a day taken 30 minutes after breakfast and dinner Amoxicillin 1.0g taken three times a day (half an hour after the meal) ,14day

Sponsors

Wuxi people’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Age range: 18 - 70 years old; 2.Patients who have been diagnosed as positive for Helicobacter pylori; 3.Patients who have not previously received Helicobacter pylori eradication treatment; 4.Patients who voluntarily participate in this trial and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Allergic to the studied drugs; 2.Patients with active peptic ulcers; 3.Patients who have received treatment for Helicobacter pylori eradication within the past six months; 4.Using adrenal cortical hormones, non-steroidal anti-inflammatory drugs or anticoagulants; 5.History of esophageal or gastric surgery; 6.Pregnant women and lactating women; 7.Having severe accompanying diseases, such as liver diseases, cardiovascular diseases, lung diseases, and kidney diseases; 8.Gastric mucosa-associated lymphoid tissue lymphoma (MALT), malignant tumor diseases;

Design outcomes

Primary

MeasureTime frame
eradication rates;

Secondary

MeasureTime frame
Compliance;Adverse event;

Countries

China

Contacts

Public ContactQinglin Zhang

Wuxi People's Hospital Affiliated to Nanjing Medical University

zhang517068@126.com+86 510 8535 1121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026